Cogent Biosciences, Inc. (COGT)
D
Pipeline Grade
Financial Position (from SEC Filings)
$241.6M
Cash & Equivalents
$86.9M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$5,897M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | PHASE3 | Active Not Recruiting | 482 |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering S... | PHASE2 | Active Not Recruiting | 237 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.